Julie Ceasar, MD
Psychiatry · Metairie, LANPI 1861680274
Payments from drug & device makers
Across 686 payments — averaging $18.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Otsuka America Pharmaceutical, Inc.$1K
- Johnson & Johnson$967
- Lundbeck LLC$874
- Alkermes, Inc.$862
- Teva Pharmaceuticals USA, Inc.$769
- plus $5K from 19 others
What the payments were for
- Food & beverage$12,24998%
- Education$2272%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 169 | $2,946 |
| Otsuka America Pharmaceutical, Inc. | 59 | $1,306 |
| Johnson & Johnson | 57 | $967 |
| Lundbeck LLC | 48 | $874 |
| Alkermes, Inc. | 43 | $862 |
| Teva Pharmaceuticals USA, Inc. | 44 | $769 |
| Axsome Therapeutics, Inc. | 33 | $645 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 52 | $640 |
| Supernus Pharmaceuticals, Inc. | 17 | $530 |
| Tris Pharma Inc | 21 | $384 |
| Neurocrine Biosciences, Inc. | 17 | $382 |
| Almatica Pharma LLC | 20 | $375 |
| Takeda Pharmaceuticals U.S.A., Inc. | 21 | $344 |
| Vanda Pharmaceuticals Inc. | 19 | $316 |
| Corium, LLC | 18 | $297 |
| Noven Therapeutics, LLC | 17 | $267 |
| Bausch Health US, LLC | 8 | $155 |
| Avanir Pharmaceuticals, Inc. | 6 | $94 |
| Jazz Pharmaceuticals Inc. | 4 | $85 |
| Idorsia Pharmaceuticals US Inc | 4 | $68 |
| Shire North American Group Inc | 2 | $47 |
| E.r. Squibb & Sons, L.L.C. | 2 | $41 |
| Acadia Pharmaceuticals Inc | 2 | $36 |
| Ironshore Pharmaceuticals Inc. | 2 | $24 |
| Adlon Therapeutics L.p. | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,476 in reported general payments places this provider in the 90th percentile of 474 psychiatry providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 71 | $107,189 |
| FanaptIloperidone | 23 | $57,623 |
| RexultiBrexpiprazole | 27 | $42,219 |
| CaplytaLumateperone Tosylate | 15 | $23,799 |
| VyvanseLisdexamfetamine Dimesylate | 60 | $23,701 |
| TrintellixVortioxetine Hydrobromide | 43 | $22,510 |
| AuvelityDextromethorphan Hbr/Bupropion | 11 | $11,148 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 346 | $10,521 |
| Duloxetine Hcl | 286 | $5,247 |
| Bupropion XlBupropion Hcl | 292 | $4,895 |
| Divalproex Sodium ErDivalproex Sodium | 52 | $3,559 |
| Paliperidone ErPaliperidone | 20 | $3,501 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 54 | $3,497 |
| Lisdexamfetamine Dimesylate | 18 | $3,324 |
| Clonazepam | 337 | $3,259 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $2,946 | $107,18971 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $316 | $57,62323 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse, Trintellix | $344 | $46,211103 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $1,306 | $42,21927 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $640 | $23,79915 claims |
| Axsome Therapeutics, Inc.Auvelity | $645 | $11,14811 claims |
| Almatica Pharma LLCSertraline Hcl | $375 | $2,116284 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 474 psychiatry providers in Louisiana.
Other psychiatry in Metairie
- Charles ChesterMetairie$14K
- Teri SchwarzMetairie$13K
- Kenneth SumnerMetairie$12K
- Jonathon RynningMetairie$11K
- Sidney SmithMetairie$10K
- Jose RodriguezMetairie$9K
- Kashinath YadalamLake Charles$3.8M
- Guy BrannonShreveport$1.4M
- Patrick HayesLake Charles$853K
- Maria CruseThibodaux$522K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.